Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.36
TROV's Cash to Debt is ranked higher than
64% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. TROV: 2.36 )
TROV' s 10-Year Cash to Debt Range
Min: 2.36   Max: No Debt
Current: 2.36

Equity to Asset 0.48
TROV's Equity to Asset is ranked higher than
61% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. TROV: 0.48 )
TROV' s 10-Year Equity to Asset Range
Min: -4.07   Max: 0.75
Current: 0.48

-4.07
0.75
F-Score: 3
Z-Score: 0.39
M-Score: -3.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4127.80
TROV's Operating margin (%) is ranked higher than
52% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. TROV: -4127.80 )
TROV' s 10-Year Operating margin (%) Range
Min: -4127.8   Max: -1077.56
Current: -4127.8

-4127.8
-1077.56
Net-margin (%) -4560.23
TROV's Net-margin (%) is ranked higher than
52% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. TROV: -4560.23 )
TROV' s 10-Year Net-margin (%) Range
Min: -4560.23   Max: -867.83
Current: -4560.23

-4560.23
-867.83
ROE (%) -57.92
TROV's ROE (%) is ranked higher than
60% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. TROV: -57.92 )
TROV' s 10-Year ROE (%) Range
Min: -533.24   Max: -57.92
Current: -57.92

-533.24
-57.92
ROA (%) -43.49
TROV's ROA (%) is ranked higher than
62% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. TROV: -43.49 )
TROV' s 10-Year ROA (%) Range
Min: -1064.26   Max: -43.49
Current: -43.49

-1064.26
-43.49
ROC (Joel Greenblatt) (%) -1423.57
TROV's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. TROV: -1423.57 )
TROV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -17351.61   Max: -1423.57
Current: -1423.57

-17351.61
-1423.57
» TROV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.50
TROV's P/B is ranked higher than
73% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. TROV: 4.50 )
TROV' s 10-Year P/B Range
Min: 3.19   Max: 100.2
Current: 4.5

3.19
100.2
EV-to-EBIT -4.52
TROV's EV-to-EBIT is ranked higher than
53% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TROV: -4.52 )
TROV' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.52

Current Ratio 17.70
TROV's Current Ratio is ranked higher than
95% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. TROV: 17.70 )
TROV' s 10-Year Current Ratio Range
Min: 0.46   Max: 20.57
Current: 17.7

0.46
20.57
Quick Ratio 17.70
TROV's Quick Ratio is ranked higher than
95% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. TROV: 17.70 )
TROV' s 10-Year Quick Ratio Range
Min: 0.46   Max: 20.57
Current: 17.7

0.46
20.57

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.90
TROV's Price/Net Cash is ranked higher than
89% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TROV: 4.90 )
TROV' s 10-Year Price/Net Cash Range
Min: 4.18   Max: 208.67
Current: 4.9

4.18
208.67
Price/Net Current Asset Value 4.90
TROV's Price/Net Current Asset Value is ranked higher than
89% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 169.30 vs. TROV: 4.90 )
TROV' s 10-Year Price/Net Current Asset Value Range
Min: 4.18   Max: 156.5
Current: 4.9

4.18
156.5
Price/Tangible Book 4.50
TROV's Price/Tangible Book is ranked higher than
79% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 8.60 vs. TROV: 4.50 )
TROV' s 10-Year Price/Tangible Book Range
Min: 3.82   Max: 62.6
Current: 4.5

3.82
62.6
Price/Median PS Value 2.00
TROV's Price/Median PS Value is ranked higher than
93% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. TROV: 2.00 )
TROV' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 2.7
Current: 2

0.08
2.7

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:XE7A.Germany
TrovaGene, Inc., was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology. As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The company's primary focuses are to leverage its urine-based testing platform to facilitate improvements in the management of Cancer Care and women's Healthcare. Tr-DNAs and Tr-RNAs are fragments of nucleic acids derived from dying cells inside the body. The intact DNA is fragmented in dying cells and released into the blood stream.
» More Articles for TROV

Headlines

Articles On GuruFocus.com
No related article found.

More From Our Partners
Morning Market Movers Aug 18 2014 - BENZINGA
TrovaGene (TROV) Worth Watching: Stock Rises 8.8% - Tale of the Tape Aug 18 2014 - ZACKS

More From Other Websites
Can the Rally in TrovaGene (TROV) Shares Continue? Aug 22 2014
TROVAGENE, INC. Files SEC form 8-K, Other Events Aug 20 2014
Trovagene Provides Update on Its Urine-Based HPV Test Aug 20 2014
Trovagene Provides Update on Its Urine-Based HPV Test Aug 20 2014
TROVAGENE, INC. Financials Aug 19 2014
TrovaGene (TROV) Worth Watching: Stock Rises 8.8% Aug 18 2014
Leader in Targeted Drug Development, Peter Hirth, Ph.D., Joins Trovagene's Scientific Advisory Board Aug 12 2014
TrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy? Aug 12 2014
Leader in Targeted Drug Development, Peter Hirth, Ph.D., Joins Trovagene's Scientific Advisory Board Aug 12 2014
TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 08 2014
Trovagene, Inc. Announces Second Quarter 2014 Financial Results Aug 07 2014
TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
Q2 2014 Trovagene Inc Earnings Release - 4:00 pm ET Aug 07 2014
Trovagene Schedules Release of Second Quarter 2014 Financial Results and Investor Conference Call Jul 30 2014
Trovagene Schedules Release of Second Quarter 2014 Financial Results and Investor Conference Call Jul 30 2014
Coverage initiated on TrovaGene by Maxim Group Jul 10 2014
Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance Jul 01 2014
TROVAGENE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Jul 01 2014
Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance Jul 01 2014
Trovagene enters into strategic alliance with Lurie Cancer Center, NMDTI Jun 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide